Jeffrey Hung
Stock Analyst at Morgan Stanley
(3.55)
# 1,001
Out of 4,479 analysts
132
Total ratings
47.31%
Success rate
4.81%
Average return
Main Sectors:
Top Industries:
32 Stocks
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| NBIX Neurocrine Biosciences | Maintains: Overweight | $160 | $137.49 | +16.37% | 11 | Jun 12, 2024 | |
| CRNX Crinetics Pharmaceuticals | Maintains: Overweight | $50 → $70 | $45.54 | +53.71% | 2 | May 23, 2024 | |
| FOLD Amicus Therapeutics | Maintains: Overweight | $20 → $19 | $9.85 | +92.89% | 2 | May 10, 2024 | |
| CTNM Contineum Therapeutics | Initiates: Overweight | $25 | $20.69 | +20.83% | 1 | Apr 30, 2024 | |
| PTCT PTC Therapeutics | Upgrades: Equal-Weight | $28 → $30 | $30.39 | -1.28% | 7 | Apr 29, 2024 | |
| IRON Disc Medicine | Maintains: Equal-Weight | $75 → $40 | $41.62 | -3.89% | 5 | Apr 2, 2024 | |
| ACAD ACADIA Pharmaceuticals | Maintains: Overweight | $40 → $30 | $15.84 | +89.39% | 16 | Mar 13, 2024 | |
| ENGN enGene Holdings | Initiates: Overweight | $40 | $8.99 | +344.94% | 1 | Mar 8, 2024 | |
| CGON CG Oncology | Initiates: Overweight | $55 | $31.32 | +75.61% | 1 | Feb 20, 2024 | |
| CYTK Cytokinetics | Downgrades: Equal-Weight | $60 → $90 | $54.84 | +64.11% | 6 | Jan 5, 2024 | |
| PRLD Prelude Therapeutics | Downgrades: Underweight | $10 → $4 | $3.73 | +7.24% | 7 | Dec 19, 2023 | |
| VIGL Vigil Neuroscience | Downgrades: Underweight | $13 → $4 | $4.01 | -0.12% | 1 | Dec 19, 2023 | |
| RYTM Rhythm Pharmaceuticals | Upgrades: Overweight | $29 → $55 | $42.34 | +29.90% | 9 | Dec 19, 2023 | |
| IVVD Invivyd | Upgrades: Equal-Weight | $1 → $4 | $1.10 | +263.64% | 1 | Dec 19, 2023 | |
| BLUE bluebird bio | Upgrades: Equal-Weight | $3 → $7 | $0.92 | +658.31% | 1 | Dec 8, 2023 | |
| RARE Ultragenyx Pharmaceutical | Maintains: Overweight | $90 → $84 | $40.96 | +105.08% | 7 | Nov 3, 2023 | |
| BCYC Bicycle Therapeutics | Maintains: Equal-Weight | $42 → $40 | $19.81 | +101.92% | 4 | Nov 3, 2023 | |
| ITCI Intra-Cellular Therapies | Reiterates: Overweight | $80 | $68.54 | +16.72% | 4 | Aug 4, 2023 | |
| IMRX Immuneering | Maintains: Equal-Weight | $14 | $1.09 | +1,184.40% | 3 | Aug 4, 2023 | |
| JAZZ Jazz Pharmaceuticals | Reiterates: Equal-Weight | $187 | $105.09 | +77.94% | 3 | Jul 11, 2023 | |
| ADCT ADC Therapeutics | Reiterates: Equal-Weight | $5 | $3.48 | +43.68% | 1 | Jul 11, 2023 | |
| ESPR Esperion Therapeutics | Maintains: Equal-Weight | $9 → $3 | $2.34 | +28.21% | 7 | Mar 20, 2023 | |
| RPTX Repare Therapeutics | Maintains: Equal-Weight | $15 → $14 | $3.24 | +332.10% | 5 | Feb 27, 2023 | |
| CGEM Cullinan Oncology | Maintains: Overweight | $27 → $19 | $16.31 | +16.49% | 4 | Feb 3, 2023 | |
| ERAS Erasca | Upgrades: Overweight | $15 | $2.32 | +546.55% | 2 | Feb 3, 2023 | |
| CELU Celularity | Downgrades: Underweight | $50 → $10 | $3.11 | +222.06% | 3 | Jan 30, 2023 | |
| EXEL Exelixis | Maintains: Equal-Weight | $23 → $22 | $22.15 | -0.68% | 2 | Nov 2, 2022 | |
| EVFM Evofem Biosciences | Maintains: Underweight | $250 → $94 | $0.01 | +852,172.73% | 8 | Jul 15, 2022 | |
| BHVN Biohaven Pharmaceutical Holding Company | Maintains: Equal-Weight | $146 → $149 | $34.17 | +334.59% | 2 | May 11, 2022 | |
| APRE Aprea Therapeutics | Downgrades: Underweight | n/a | $3.80 | - | 3 | Aug 13, 2021 | |
| VYGR Voyager Therapeutics | Maintains: Equal-Weight | n/a | $7.59 | - | 2 | Feb 3, 2021 | |
| NXTC NextCure | Maintains: Overweight | n/a | $1.50 | - | 1 | Apr 15, 2020 |
Neurocrine Biosciences
Jun 12, 2024
Maintains: Overweight
Price Target: $160
Current: $137.49
Upside: +16.37%
Crinetics Pharmaceuticals
May 23, 2024
Maintains: Overweight
Price Target: $50 → $70
Current: $45.54
Upside: +53.71%
Amicus Therapeutics
May 10, 2024
Maintains: Overweight
Price Target: $20 → $19
Current: $9.85
Upside: +92.89%
Contineum Therapeutics
Apr 30, 2024
Initiates: Overweight
Price Target: $25
Current: $20.69
Upside: +20.83%
PTC Therapeutics
Apr 29, 2024
Upgrades: Equal-Weight
Price Target: $28 → $30
Current: $30.39
Upside: -1.28%
Disc Medicine
Apr 2, 2024
Maintains: Equal-Weight
Price Target: $75 → $40
Current: $41.62
Upside: -3.89%
ACADIA Pharmaceuticals
Mar 13, 2024
Maintains: Overweight
Price Target: $40 → $30
Current: $15.84
Upside: +89.39%
enGene Holdings
Mar 8, 2024
Initiates: Overweight
Price Target: $40
Current: $8.99
Upside: +344.94%
CG Oncology
Feb 20, 2024
Initiates: Overweight
Price Target: $55
Current: $31.32
Upside: +75.61%
Cytokinetics
Jan 5, 2024
Downgrades: Equal-Weight
Price Target: $60 → $90
Current: $54.84
Upside: +64.11%
Prelude Therapeutics
Dec 19, 2023
Downgrades: Underweight
Price Target: $10 → $4
Current: $3.73
Upside: +7.24%
Vigil Neuroscience
Dec 19, 2023
Downgrades: Underweight
Price Target: $13 → $4
Current: $4.01
Upside: -0.12%
Rhythm Pharmaceuticals
Dec 19, 2023
Upgrades: Overweight
Price Target: $29 → $55
Current: $42.34
Upside: +29.90%
Invivyd
Dec 19, 2023
Upgrades: Equal-Weight
Price Target: $1 → $4
Current: $1.10
Upside: +263.64%
bluebird bio
Dec 8, 2023
Upgrades: Equal-Weight
Price Target: $3 → $7
Current: $0.92
Upside: +658.31%
Ultragenyx Pharmaceutical
Nov 3, 2023
Maintains: Overweight
Price Target: $90 → $84
Current: $40.96
Upside: +105.08%
Bicycle Therapeutics
Nov 3, 2023
Maintains: Equal-Weight
Price Target: $42 → $40
Current: $19.81
Upside: +101.92%
Intra-Cellular Therapies
Aug 4, 2023
Reiterates: Overweight
Price Target: $80
Current: $68.54
Upside: +16.72%
Immuneering
Aug 4, 2023
Maintains: Equal-Weight
Price Target: $14
Current: $1.09
Upside: +1,184.40%
Jazz Pharmaceuticals
Jul 11, 2023
Reiterates: Equal-Weight
Price Target: $187
Current: $105.09
Upside: +77.94%
ADC Therapeutics
Jul 11, 2023
Reiterates: Equal-Weight
Price Target: $5
Current: $3.48
Upside: +43.68%
Esperion Therapeutics
Mar 20, 2023
Maintains: Equal-Weight
Price Target: $9 → $3
Current: $2.34
Upside: +28.21%
Repare Therapeutics
Feb 27, 2023
Maintains: Equal-Weight
Price Target: $15 → $14
Current: $3.24
Upside: +332.10%
Cullinan Oncology
Feb 3, 2023
Maintains: Overweight
Price Target: $27 → $19
Current: $16.31
Upside: +16.49%
Erasca
Feb 3, 2023
Upgrades: Overweight
Price Target: $15
Current: $2.32
Upside: +546.55%
Celularity
Jan 30, 2023
Downgrades: Underweight
Price Target: $50 → $10
Current: $3.11
Upside: +222.06%
Exelixis
Nov 2, 2022
Maintains: Equal-Weight
Price Target: $23 → $22
Current: $22.15
Upside: -0.68%
Evofem Biosciences
Jul 15, 2022
Maintains: Underweight
Price Target: $250 → $94
Current: $0.01
Upside: +852,172.73%
Biohaven Pharmaceutical Holding Company
May 11, 2022
Maintains: Equal-Weight
Price Target: $146 → $149
Current: $34.17
Upside: +334.59%
Aprea Therapeutics
Aug 13, 2021
Downgrades: Underweight
Price Target: n/a
Current: $3.80
Upside: -
Voyager Therapeutics
Feb 3, 2021
Maintains: Equal-Weight
Price Target: n/a
Current: $7.59
Upside: -
NextCure
Apr 15, 2020
Maintains: Overweight
Price Target: n/a
Current: $1.50
Upside: -